Available Until 6/9/2028

Summit on Advanced Therapeutics - Management of Advanced Therapeutics Across the Healthcare Continuum

There is no CE associated with this activity
Release Date:  June 09, 2025
Expiration Date: June 09, 2028
Activity Fee: Free for members
This session was part of ASHP’s Summit on Advanced Therapeutics at Pharmacy Futures 2025. There is no CE associated with this activity.

Activity Overview 

This activity will include an in-depth exploration of the evolving landscape of advanced therapeutics management across the healthcare continuum. Viewers will learn collaborative strategies essential for ensuring continuity of care for patients requiring advanced therapies, emphasizing operational, personnel, clinical, and monitoring considerations. 

   
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

This activity is intended to meet the professional development needs of Certified Pharmacy Executive Leaders.  

  • Introduction and Announcements 

  • Presentation  

  • Questions, Answers, and Discussion 

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

  • No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.